Omnicell, Inc. $OMCL Stock Holdings Decreased by CenterBook Partners LP

CenterBook Partners LP lowered its stake in shares of Omnicell, Inc. (NASDAQ:OMCL) by 78.5% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,152 shares of the company’s stock after selling 44,456 shares during the quarter. CenterBook Partners LP’s holdings in Omnicell were worth $414,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. BlackRock Inc. purchased a new position in Omnicell in the second quarter valued at about $313,044,000. First Light Asset Management LLC purchased a new stake in shares of Omnicell during the first quarter valued at about $16,351,000. Fort Washington Investment Advisors Inc. OH bought a new stake in shares of Omnicell in the 3rd quarter valued at about $15,620,000. WCM Investment Management LLC bought a new stake in shares of Omnicell in the 1st quarter valued at about $9,783,000. Finally, Empowered Funds LLC grew its position in shares of Omnicell by 4,229.9% in the 1st quarter. Empowered Funds LLC now owns 262,043 shares of the company’s stock worth $8,747,000 after buying an additional 255,991 shares during the last quarter. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on OMCL. Wall Street Zen lowered shares of Omnicell from a “strong-buy” rating to a “buy” rating in a research note on Saturday, November 7th. Wells Fargo & Company lowered their target price on shares of Omnicell from $55.00 to $50.00 and set an “overweight” rating for the company in a research note on Friday, July 31st. KeyCorp reaffirmed an “overweight” rating on shares of Omnicell in a report on Monday, August 24th. Piper Sandler reaffirmed an “overweight” rating and set a $45.00 price target (down from $55.00) on shares of Omnicell in a research report on Monday, August 3rd. Finally, Zacks Research upgraded Omnicell from a “hold” rating to a “strong-buy” rating in a report on Wednesday, November 4th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $57.86.

Omnicell Trading Down 1.7%

Omnicell stock opened at $34.95 on Friday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.45 and a current ratio of 1.65. The stock has a market cap of $1.61 billion, a PE ratio of 36.41, a price-to-earnings-growth ratio of 0.89 and a beta of 0.88. The stock has a 50-day moving average of $35.06 and a two-hundred day moving average of $38.49. Omnicell, Inc. has a one year low of $31.75 and a one year high of $55.00.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings results on Thursday, October 29th. The company reported $0.58 earnings per share for the quarter, topping analysts’ consensus estimates of $0.42 by $0.16. Omnicell had a return on equity of 5.69% and a net margin of 3.59%. The business had revenue of $307.85 million for the quarter, compared to analyst estimates of $304.44 million. During the same quarter in the previous year, the firm earned $0.51 earnings per share. The company’s revenue was down .9% on a year-over-year basis. On average, research analysts anticipate that Omnicell, Inc. will post 1.64 EPS for the current fiscal year.

Omnicell Company Profile

Omnicell, Inc. develops medication-management solutions for healthcare providers. Its products and services are designed to help manage medication storage, dispensing, inventory and workflows across healthcare settings. The company offers automated dispensing cabinets for patient-care areas, automation systems for central pharmacies, and software and analytics that support medication management. Its solutions serve hospitals, health systems, pharmacies and other care providers, including long-term and post-acute care organizations.